Selected research
Industry Research
Inhaled NO Vasodilator Industry Research Report 2026
Market perspective
The global Inhaled NO Vasodilator market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Inhaled NO Vasodilator is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Inhaled NO Vasodilator is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Inhaled NO Vasodilator is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Inhaled NO Vasodilator include Air Liquide, BOC Healthcare (Linde Group), Mallinckrodt and Praxair (Linde plc), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Inhaled NO Vasodilator market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Inhaled NO Vasodilator Market by Company
Air Liquide
BOC Healthcare (Linde Group)
Mallinckrodt
Praxair (Linde plc)
Inhaled NO Vasodilator Segment by Type
800 ppm
100 ppm
Others
Inhaled NO Vasodilator Segment by Application
PPHN
ARDS
Others
Inhaled NO Vasodilator Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inhaled NO Vasodilator market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inhaled NO Vasodilator and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inhaled NO Vasodilator.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Inhaled NO Vasodilator manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Inhaled NO Vasodilator by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Inhaled NO Vasodilator in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 800 ppm
- 100 ppm
- Others
Applications
- PPHN
- ARDS
- Others
Companies covered
- Air Liquide
- BOC Healthcare (Linde Group)
- Mallinckrodt
- Praxair (Linde plc)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Inhaled NO Vasodilator Market Size (2021-2032)
- 2.2.2 Global Inhaled NO Vasodilator Sales (2021-2032)
- 2.2.3 Global Inhaled NO Vasodilator Market Average Price (2021-2032)
- 2.3 Inhaled NO Vasodilator by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 800 ppm
- 2.3.3 100 ppm
- 2.3.4 Others
- 2.4 Inhaled NO Vasodilator by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 PPHN
- 2.4.3 ARDS
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Inhaled NO Vasodilator Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Inhaled NO Vasodilator Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Inhaled NO Vasodilator Revenue of Manufacturers (2021-2026)
- 3.4 Global Inhaled NO Vasodilator Average Price by Manufacturers (2021-2026)
- 3.5 Global Inhaled NO Vasodilator Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Inhaled NO Vasodilator, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Inhaled NO Vasodilator, Product Type & Application
- 3.8 Global Manufacturers of Inhaled NO Vasodilator, Established Date
- 3.9 Global Inhaled NO Vasodilator Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Air Liquide
- 4.1.1 Air Liquide Company Information
- 4.1.2 Air Liquide Business Overview
- 4.1.3 Air Liquide Inhaled NO Vasodilator Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Air Liquide Inhaled NO Vasodilator Product Portfolio
- 4.1.5 Air Liquide Recent Developments
- 4.2 BOC Healthcare (Linde Group)
- 4.2.1 BOC Healthcare (Linde Group) Company Information
- 4.2.2 BOC Healthcare (Linde Group) Business Overview
- 4.2.3 BOC Healthcare (Linde Group) Inhaled NO Vasodilator Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 BOC Healthcare (Linde Group) Inhaled NO Vasodilator Product Portfolio
- 4.2.5 BOC Healthcare (Linde Group) Recent Developments
- 4.3 Mallinckrodt
- 4.3.1 Mallinckrodt Company Information
- 4.3.2 Mallinckrodt Business Overview
- 4.3.3 Mallinckrodt Inhaled NO Vasodilator Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mallinckrodt Inhaled NO Vasodilator Product Portfolio
- 4.3.5 Mallinckrodt Recent Developments
- 4.4 Praxair (Linde plc)
- 4.4.1 Praxair (Linde plc) Company Information
- 4.4.2 Praxair (Linde plc) Business Overview
- 4.4.3 Praxair (Linde plc) Inhaled NO Vasodilator Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Praxair (Linde plc) Inhaled NO Vasodilator Product Portfolio
- 4.4.5 Praxair (Linde plc) Recent Developments
5 Global Inhaled NO Vasodilator Market Scenario by Region
- 5.1 Global Inhaled NO Vasodilator Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Inhaled NO Vasodilator Sales by Region: 2021-2032
- 5.2.1 Global Inhaled NO Vasodilator Sales by Region: 2021-2026
- 5.2.2 Global Inhaled NO Vasodilator Sales by Region: 2027-2032
- 5.3 Global Inhaled NO Vasodilator Revenue by Region: 2021-2032
- 5.3.1 Global Inhaled NO Vasodilator Revenue by Region: 2021-2026
- 5.3.2 Global Inhaled NO Vasodilator Revenue by Region: 2027-2032
- 5.4 North America Inhaled NO Vasodilator Market Facts & Figures by Country
- 5.4.1 North America Inhaled NO Vasodilator Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Inhaled NO Vasodilator Sales by Country (2021-2032)
- 5.4.3 North America Inhaled NO Vasodilator Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Inhaled NO Vasodilator Market Facts & Figures by Country
- 5.5.1 Europe Inhaled NO Vasodilator Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Inhaled NO Vasodilator Sales by Country (2021-2032)
- 5.5.3 Europe Inhaled NO Vasodilator Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Inhaled NO Vasodilator Market Facts & Figures by Country
- 5.6.1 Asia Pacific Inhaled NO Vasodilator Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Inhaled NO Vasodilator Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Inhaled NO Vasodilator Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Inhaled NO Vasodilator Market Facts & Figures by Country
- 5.7.1 South America Inhaled NO Vasodilator Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Inhaled NO Vasodilator Sales by Country (2021-2032)
- 5.7.3 South America Inhaled NO Vasodilator Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Inhaled NO Vasodilator Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Inhaled NO Vasodilator Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Inhaled NO Vasodilator Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Inhaled NO Vasodilator Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Inhaled NO Vasodilator Sales by Type (2021-2032)
- 6.1.1 Global Inhaled NO Vasodilator Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Inhaled NO Vasodilator Sales Market Share by Type (2021-2032)
- 6.2 Global Inhaled NO Vasodilator Revenue by Type (2021-2032)
- 6.2.1 Global Inhaled NO Vasodilator Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Inhaled NO Vasodilator Revenue Market Share by Type (2021-2032)
- 6.3 Global Inhaled NO Vasodilator Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Inhaled NO Vasodilator Sales by Application (2021-2032)
- 7.1.1 Global Inhaled NO Vasodilator Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Inhaled NO Vasodilator Sales Market Share by Application (2021-2032)
- 7.2 Global Inhaled NO Vasodilator Revenue by Application (2021-2032)
- 7.2.1 Global Inhaled NO Vasodilator Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Inhaled NO Vasodilator Revenue Market Share by Application (2021-2032)
- 7.3 Global Inhaled NO Vasodilator Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Inhaled NO Vasodilator Value Chain Analysis
- 8.1.1 Inhaled NO Vasodilator Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Inhaled NO Vasodilator Production Mode & Process
- 8.2 Inhaled NO Vasodilator Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Inhaled NO Vasodilator Distributors
- 8.2.3 Inhaled NO Vasodilator Customers
9 Global Inhaled NO Vasodilator Analyzing Market Dynamics
- 9.1 Inhaled NO Vasodilator Industry Trends
- 9.2 Inhaled NO Vasodilator Industry Drivers
- 9.3 Inhaled NO Vasodilator Industry Opportunities and Challenges
- 9.4 Inhaled NO Vasodilator Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst